Adjuvant abemaciclib combined with endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) in patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). The impact on overall survival (OS) remained unknown.
Overall survival with abemaciclib in early breast cancer☆
Annals of Oncology | | S. Johnston, M. Martin, J. O’Shaughnessy, R. Hegg, S.M. Tolaney, V. Guarneri, L. Del Mastro, M. Campone, J. Sohn, F. Boyle, J. Cortes, H.S. Rugo, M.P. Goetz, E.P. Hamilton, C.-S. Huang, E. Senkus, I. Cicin, L. Testa, P. Neven, J. Huober, Z. Shao, R. Wei, M. Munoz, B. San Antonio, A. Shahir, P. Rastogi, N. Harbeck
Topics: breast-cancer, blood-cancer, clinical-trials